Distribution · GCC · Announced 21 Oct 2026
Mubadala Bio → Jamjoom Pharma
Distribution deal between Mubadala Bio (United Arab Emirates) and Jamjoom Pharma (Saudi Arabia), covering Unnamed biologic therapy, announced 21 Oct 2026.
Parties: Mubadala Bio (United Arab Emirates) → Jamjoom Pharma (Saudi Arabia)
- Deal type
- Distribution
- Value
- Not stated
- Territory
- United Arab Emirates
- Therapeutic area
- Immunology / Inflammation
- Asset
- Unnamed biologic therapy — BVH provides product, supply and quality capabilities; Jamjoom = exclusive commercial arm (UAE)
- Announced
- 21 Oct 2026
Our analysis
Why this matters
The UAE's sovereign biologics manufacturer and the Gulf's most aggressive biologics commercializer just formalized their pairing. Mubadala Bio's Bioventure Healthcare — a Kelix Bio/GHH asset with ~113 product registrations (105 in UAE) including adalimumab — appointed Jamjoom Pharma exclusive commercial arm for a biologic therapy in the UAE.
For BD: the supply/commercialization unbundling — BVH owns product, supply and quality; Jamjoom owns outreach, scale and medical education — is becoming the region's default biologics go-to-market.
The full analysis is free to read with a work email on this page.